Efficacy and safety of biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in insulin naive type 2 diabetic patients with secondary OHA [oral hypoglycaemic agent] failure
Phase of Trial: Phase IV
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 15 May 2009 Actual patient number (71) added as reported by ClinicalTrials.gov.
- 15 May 2009 Actual end date (Jan 2005) added as reported by ClinicalTrials.gov.